The Might of Mesoblast: How Perseverance Paid Off
Last year, Mesoblast Ltd had their therapeutic RYONCIL approved by the FDA. This article touches on the journey to get to this milestone.
Here’s why last week’s stock market crash is a warning sign for Australia’s biotech sector
Investments in biotechnology are most impactful when made by those with deep pockets. The aim of the game is to make a return on investment, which can only occur when biotech companies can create a profitable product. Without funding from angel investors/venture capitalists, many biotech companies cannot continue to meaningfully function. Analysis of the recent …
How Right Were We? – A Recap Of The Most Promising Biotech Companies In 2024.
We’re halfway! As we have reached the first half of 2024, I feel it is time to revisit our previous article and check-in with the companies we identified as interesting to look out for in 2024. This mid-year update revisits our list of the top biotech companies to watch, providing insights into their performance, developments, …
Read more “How Right Were We? – A Recap Of The Most Promising Biotech Companies In 2024.”
Big day for Aussie biotech: NSB and MSB soar
Two Australian stock exchange listed biotech companies, Neuroscientific Biopharmaceuticals LTD and Mesoblast LTD, have experienced upward spikes in share price as a result of positive news released over the Easter holiday.
Oh, Canada: Exopharm acquire Tryp Therapeutics
In a move known as a reverse merger, Exopharm Ltd have acquired Canadian biotech company Tryp Therapeutics, who will occupy Exopharm’s place on the ASX.
Top 4 Biotech companies to look out for in 2024
In this article.. The biotechnology industry is constantly evolving, with new companies emerging and established players making advancements every day. As we move through 2024, It’s important to recognise which companies are poised to make a significant impact. Currently, the market is leaning optimistically due to the high number of acquisitions into bopharma companies performed …